Back to Search
PAULA LUKAS, PHARMD
PHARMD
Pharmacist
NPI: 1215206511Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
13445-040(WI)
Pharmacotherapy Pharmacist
Pharmacist — Pharmacotherapy
Code: 1835P1200X
13445-040(WI)
Research & Publications (20)
Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry.
PMID 19397483·Clin Chem Lab Med·2009
8-other
Compensating for tumor motion by a 6-degree-of-freedom treatment couch: is patient tolerance an issue?
PMID 19167841·Int J Radiat Oncol Biol Phys·2009
8-other
Postoperative morbidity following chemoradiation for locally advanced low rectal cancer.
PMID 19082672·J Gastrointest Surg·2009
8-other
Treatment of vascular soft tissue sarcomas with razoxane, vindesine, and radiation.
PMID 19004568·Int J Radiat Oncol Biol Phys·2009
3-trial
Quality control of involved field radiotherapy in patients with early-favorable (HD10) and early-unfavorable (HD11) Hodgkin's lymphoma: an analysis of the German Hodgkin Study Group.
PMID 18234433·Int J Radiat Oncol Biol Phys·2008
4-observational
Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells.
PMID 18821526·Proteomics·2008
8-other
Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG).
PMID 18956517·Strahlenther Onkol·2008
4-observational
Photons or protons: precision radiotherapy of lung cancer.
PMID 18166995·Strahlenther Onkol·2007
4-observational
Single-institution results of primary external-beam radiation for the treatment of t1-t3 prostate cancer.
PMID 17520186·Strahlenther Onkol·2007
8-other
Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines.
PMID 17575118·Mol Cancer Ther·2007
8-other
MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
PMID 17575155·Cancer Res·2007
7-preclinical
Optimized conformal paraaortic lymph node irradiation is not associated with enhanced renal toxicity.
PMID 17609872·Strahlenther Onkol·2007
2-rct
Progress in Radio-Oncology VIII. Proceedings of the 8th International Meeting on Progress in Radio-Oncology ICRO/OGRO 8.
PMID 18166994·Strahlenther Onkol·2007
8-other
Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.
PMID 16819145·J Radiat Res·2006
8-other
Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.
PMID 16151650·Apoptosis·2005
8-other
Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.
PMID 15976970·J Thromb Thrombolysis·2005
5-case
Competing irradiation techniques for para-aortic lymph nodes: dose distribution and NTCP for the kidney.
PMID 15978740·Int J Radiat Oncol Biol Phys·2005
8-other
Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.
PMID 15988143·J Radiat Res·2005
4-observational
The med AUSTRON/OGRO patterns of care study on radiotherapy indications in Austria.
PMID 15971305·Radiother Oncol·2004
8-other
The patient positioning concept for the planned MedAustron centre.
PMID 15971312·Radiother Oncol·2004
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1021 SUMMIT AVE
OCONOMOWOC, WI 53066 - Phone
- (262) 567-9173
Quick Facts
- NPI
- 1215206511
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile